The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
Issued Date
2023-05-01
Resource Type
ISSN
14741733
eISSN
14741741
Scopus ID
2-s2.0-85144452287
Pubmed ID
36539527
Journal Title
Nature Reviews Immunology
Volume
23
Issue
5
Start Page
304
End Page
316
Rights Holder(s)
SCOPUS
Bibliographic Citation
Nature Reviews Immunology Vol.23 No.5 (2023) , 304-316
Suggested Citation
Murray S.M., Ansari A.M., Frater J., Klenerman P., Dunachie S., Barnes E., Ogbe A. The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses. Nature Reviews Immunology Vol.23 No.5 (2023) , 304-316. 316. doi:10.1038/s41577-022-00809-x Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82065
Title
The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
Other Contributor(s)
Abstract
Pre-existing cross-reactive immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins in infection-naive subjects have been described by several studies. In particular, regions of high homology between SARS-CoV-2 and common cold coronaviruses have been highlighted as a likely source of this cross-reactivity. However, the role of such cross-reactive responses in the outcome of SARS-CoV-2 infection and vaccination is currently unclear. Here, we review evidence regarding the impact of pre-existing humoral and T cell immune responses to outcomes of SARS-CoV-2 infection and vaccination. Furthermore, we discuss the importance of conserved coronavirus epitopes for the rational design of pan-coronavirus vaccines and consider cross-reactivity of immune responses to ancestral SARS-CoV-2 and SARS-CoV-2 variants, as well as their impact on COVID-19 vaccination.